文献速递胸部肿瘤放疗中枢神经肿瘤放疗

新辅助奥希替尼序贯根治性放疗和/或手术用于III期表皮生长因子受体突变非小细胞肺癌:一项开放标签、单臂、2期研究

Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-03-15

这项开放标签、单臂、2期前瞻性概念验证研究纳入24例初治不可手术的III期EGFR突变NSCLC患者,每日口服奥希替尼80 mg共12周后行根治性放疗和/或手术。诱导奥希替尼的客观缓解率为95.2%,放疗靶区体积显著缩小,未报告显著不良事件。

要点

  • 诱导奥希替尼12周后客观缓解率达95.2%(17例部分缓解、3例完全缓解、1例疾病进展)。
  • 奥希替尼诱导后GTV、PTV和V20%均较治疗前显著降低,分别降低约48%、31%和24%。
  • 奥希替尼或放疗阶段未报告显著不良事件。

核心结论

  • 新辅助奥希替尼治疗在III期NSCLC患者中可行,随后行根治性放疗和/或手术,客观缓解率为95.2%,安全性良好。
  • 根治性放疗前12周奥希替尼诱导(无化疗)使放疗野缩小近50%,且与肿瘤大小呈线性相关。
  • 在改变临床实践前,需要进一步研究来检验这种无化疗方案的长期结局。

研究设计与样本

  • 本研究为非随机、开放标签、单臂、2期、前瞻性、概念验证研究。
  • 纳入标准为初治、不可手术的III期EGFR突变NSCLC患者。
  • 患者每日口服奥希替尼80 mg,共12周,之后行根治性放疗和/或手术;缓解者在第6周和第12周评估,无缓解者开始标准同步放化疗。
  • 放疗±手术或同步放化疗后随访2年,不做辅助治疗;主要终点为客观缓解率,数据收集截止日期为2022年9月20日。
  • 共纳入24例患者(19例女性;中位年龄73岁,范围51-82岁);19/24从未吸烟,20/24为腺癌,16/24有外显子19缺失,8/24有外显子21突变;分期为IIIA期10例、IIIB期9例、IIIC期5例。

主要发现

  • 3例患者被排除分析(1例退出,2例在截止日期时仍在接受奥希替尼治疗)。
  • 诱导奥希替尼的客观缓解率为95.2%(17例部分缓解、3例完全缓解、1例疾病进展)。
  • 诱导奥希替尼后,20例患者中13例行根治性放疗、3例行手术、5例被排除;4例重新分期为IV期(对侧磨玻璃影对奥希替尼有反应),1例撤回知情同意。
  • 3例患者接受手术,其中1例接受了放疗;2例达到pT1aN0,1例达到病理完全缓解。
  • 奥希替尼治疗前中位GTV为47.4 ± 76.9 cm3(13.5-234.9),PTV为227.0 ± 258.8 cm3(77.8-929.2),V20%为27.1 ± 16.4%(6.2-60.3)。

关键数值与推荐

  • 客观缓解率为95.2%,包括17例部分缓解、3例完全缓解和1例疾病进展。
  • 奥希替尼治疗后GTV较治疗前降低48 ± 20%(P = .02),PTV降低31 ± 20%(P = .01),V20%降低24 ± 40%(P = .04)。
  • 中位无病生存期未达到(均值30.59个月;标准误3.94;95%置信区间22.86-38.31)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 在改变临床实践前,需要进一步研究来检验这种无化疗方案的长期结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The treatment for unresectable, locally advanced stage III non-small cell lung cancer (NSCLC) is concurrent chemoradiation therapy (CRT) followed by consolidation durvalumab. This study aimed to evaluate the benefit of neoadjuvant osimertinib as an alternative therapy to this approach with the aim of reducing the radiation field. METHODS AND MATERIALS: This investigation was a nonrandomized, open-label, single-arm, phase 2, prospective, proof-of-concept study. Eligible patients were classified as having treatment-naïve, nonoperable, stage III epidermal growth factor receptor-mutant NSCLC. Patients received 80 mg of oral osimertinib daily for 12 weeks before definitive radiation therapy (RT) and/or surgery. The response was assessed at weeks 6 and 12. For responders, sequential definitive RT and/or surgery were planned. Nonresponders were started on standard CRT. After RT ± surgery or CRT, patients were followed for 2 years without adjuvant therapy. The primary endpoint was the objective response rate (ORR), with September 20, 2022, set as the cut-off for data collection. Secondary endpoints were safety and the gross tumor volume (GTV), planned tumor volume (PTV), and the percentage of total lung volume minus GTV exceeding 20 Gy (V20%) before versus after osimertinib. Exploratory analyses included assessments of the presence of plasma circulating tumor-free DNA (ctDNA) before osimertinib treatment, at weeks 6 and 12, at the end of RT, and 6 weeks post-RT. RESULTS: Twenty-four patients were included (19 women; median age, 73 years; range, 51-82 years). Nineteen of 24 had never smoked, 20 of 24 had adenocarcinoma, 16 of 24 had exon 19 deletions, and 8 of 24 had exon 21 mutations. Participants had stage IIIA (10), IIIB (9), or IIIC (5) disease. Three patients were excluded from the analysis (1 dropped out and 2 were still undergoing osimertinib treatment at the cut-off date). The ORR to induction osimertinib was 95.2% (17 partial response, 3 complete response, and 1 progressive disease). After induction osimertinib, 13 of 20 patients were definitively radiated, 3 of 20 underwent surgery, and 5 of 20 were excluded. Four patients were restaged as stage IV (contralateral ground-glass opacities responded to osimertinib), and 1 patient withdrew informed consent. Three patients underwent surgery, one of whom was treated with RT. Two patients achieved pT1aN0, and one achieved pathologic complete response. The median GTV, PTV, and V20% before osimertinib treatment were 47.4 ± 76.9 cm3 (13.5-234.9), 227.0 ± 258.8 cm3 (77.8-929.2), and 27.1 ± 16.4% (6.2-60.3), respectively. The values after osimertinib treatment were 27.5 ± 42.3 cm3 (2.99-137.7; -48 ± 20%; P = .02), 181.9 ±198.4 cm3 (54-718.1; -31 ± 20%; P = .01), and 21.8 ± 11.7% (9.1-44.15; -24 ± 40%; P = .04), respectively. PTV/GTV/V20% reduction was associated with tumor size and central location. The median follow-up time was 28.71 months (range, 0.4-45.1 months), and median disease-free survival was not reached (mean, 30.59; standard error, 3.94; 95% confidence interval, 22.86-38.31). ctDNA was detected in 5 patients; 4 of 5 were positive for ctDNA at baseline and became negative during osimertinib induction but were again positive after osimertinib treatment was terminated. Interestingly, 3 patients who were ctDNA negative at baseline became weakly positive after RT and then were negative at follow-up. No significant adverse events were reported during the osimertinib or radiation phases. CONCLUSIONS: Neoadjuvant osimertinib therapy is feasible in patients with stage III lung cancer NSCLC, followed by definitive radiation and/or surgery, with an ORR of 95.2% and an excellent safety profile. Osimertinib induction for 12 weeks before definitive radiation (chemo-free) significantly reduced the radiation field by nearly 50% with a linear association with tumor size. Further studies are needed to test this chemo-free approach for long-term outcomes before practices are changed.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Peled N, Roisman LC, Levison E, et al. Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study. Int J Radiat Oncol Biol Phys. 2023. PMID: 36925073. doi:10.1016/j.ijrobp.2023.03.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。